Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Pelican Therapeutics
  • Technology
    • gp96 Platform
    • Pelican’s PTX-35 Co-stimulatory Antibody
  • Product Pipeline
    • Overview
    • HS-110
    • HS-130
    • COVID-19 Vaccine
    • PTX-35
    • Expanded Access
    • Scientific Publications
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Corporate Presentation
  • News & Media
    • News Releases
    • Events
  • Careers
  • Contact

News Releases

News & Media

News & Media

  • News Releases
  • Events

Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference

Feb 12, 2021

Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Feb 9, 2021

Heat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine Results

Jan 27, 2021

Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021

Jan 20, 2021

Heat Biologics Commences Manufacturing Process for ZVX-60

Jan 19, 2021

Heat Biologics Promotes William L. Ostrander to Chief Financial Officer

Jan 11, 2021

Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Jan 8, 2021

Heat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19

Dec 16, 2020

Heat Biologics Provides Business Update

Dec 10, 2020

Heat Biologics Provides Third Quarter 2020 Business Update

Nov 9, 2020
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...25
© 2021 Heat Biologics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap LinkedIn